Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of daratumumab + VRd versus VRd in transplant-ineligible newly diagnosed multiple myeloma
NL-OMON52950Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall MRD negativity rate. Started Apr 2019; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON52950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52950.